(Total Views: 525)
Posted On: 01/17/2021 7:33:49 PM
Post# of 153992
I've been using 28-35% as the range for reasons lost to the mists of time... Given 32% falls in there, I'm content to use that as well.
We also have to factor in deaths > 28 days... By the end of the study, I'm sure there will be a few. Assuming 32% in SOC and all other fatalities within 28 days in the LLMab arm may get a mortality reduction around 46%, which is great. Squarely in EUA / approval territory.
But if there are 4-6 deaths past 28 days that are being assigned to LLMab in that model, that's only going to get better.
We also have to factor in deaths > 28 days... By the end of the study, I'm sure there will be a few. Assuming 32% in SOC and all other fatalities within 28 days in the LLMab arm may get a mortality reduction around 46%, which is great. Squarely in EUA / approval territory.
But if there are 4-6 deaths past 28 days that are being assigned to LLMab in that model, that's only going to get better.
(2)
(0)
